Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1376173 | Bioorganic & Medicinal Chemistry Letters | 2008 | 4 Pages |
Abstract
Herein we describe a novel pyrazole-based class of ATP competitive B-Raf inhibitors. These inhibitors exhibit both excellent cellular potency and striking B-Raf selectivity. A subset of these inhibitors has demonstrated the ability to inhibit downstream ERK phosphorylation in LOX tumors from mouse xenograft studies.
Graphical abstractWe report herein a series of substituted pyrazoles as inhibitors of B-Raf kinase. Through structure–activity relationship studies, cellular potency, pharmacokinetics, and kinase selectivity were optimized to afford GDC-0879 (10), a compound with good preclinical in vivo activity against tumor xenograft models.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Joshua D. Hansen, Jonas Grina, Brad Newhouse, Mike Welch, George Topalov, Nicole Littman, Michele Callejo, Susan Gloor, Matthew Martinson, Ellen Laird, Barbara J. Brandhuber, Guy Vigers, Tony Morales, Rich Woessner, Nikole Randolph, Joseph Lyssikatos,